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Giorelli et al.’s case report in Tremor and Other Hyperkinetic Movements1
details a case that presented with symptoms of posterior cortical atrophy
(PCA) that later developed corticobasal syndrome (CBS). I have had
several patients who followed this clinical course, and I coincidentally
saw one of these patients in clinic just before reading the report. The
case raises several interesting controversies in the areas of diagnoses over
time and clinical–pathological agreement in dementing disorders.
Traditionally, the role of the diagnostician when seeing patients with
dementing disorders has been to use the clinical information to
determine the causative pathological process to guide prognosis and
treatment. The success of this endeavor is determined by assessing the
agreement between the clinical and post-mortem pathological
diagnoses. This model has ample precedent in medicine, notably in
infectious disease in which the connections between the clinical
syndrome and the underlying etiology can often be made in the living
patient to guide therapy (e.g., pneumonia is the clinical syndrome,
pneumococcus is the causative organism). However, this model runs
into some complications in dementing disorders.
First, clinical–pathological agreement in dementia is imperfect. It
varies between diagnoses, but ranges between approximately 50%
agreement between CBS (Corticobasal syndrome) and CBD
(Corticobasal ganglionic degeneration)2 Corticobasal syndrometo
approximately 85% for clinical and pathological Alzheimer’s disease
(AD).3 But one must keep in mind that these figures generally represent
‘‘gold standard’’ final diagnoses determined at specialized academic
centers. We would expect agreement to be lower for initial evaluations,
in patients seen in the community, and in patients with mild cognitive
impairment. Bayes’ theorem states that the pre-evaluation prevalence
of a diagnosis influences the post-evaluation probability of that
diagnosis. Thus, clinical–pathological agreement should be higher
for a common pathological cause of dementia, such as AD, than for
rarer causes of dementia, such as CBD. In general, this appears to be
true in dementing disorders with the exception of certain neuro-
pathologies that appear to have such pathognomonic clinical
presentations that clinical-pathological disagreement is rare, such as
FTD-ALS (Frontotemporal dementia-amyotrophic lateral sclerosis)
and progressive supranuclear palsy.
A second complication in clinical-pathological agreement is that
some clinical presentations, for example, behavioral variant FTD, are
compatible with several different pathologies that cannot currently be
distinguished clinically. As Giorelli et al. point out, CBS can result
from several different neuropathologies, including CBD and AD.
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A third issue in clinical–pathological agreement, exemplified in the
report by Giorelli et al., is that a single final clinical diagnosis often does
not capture the complex course of a neurodegenerative disorder. To
diagnose the patient described in this report with CBS fails to capture
her clinical course prior to meeting criteria for that diagnosis. The
majority of patients with FTD will develop related clinical syndromes
that meet criteria for other disorders over the course of their illness.4
There are likely, as yet undiscovered, biological reasons for this
heterogeneity in the course of these disorders, but these reasons may
remain obscure unless we record and study the earlier presentations of
the illness as well as the final diagnosis. While the saying ‘‘the last doctor
is the smartest’’ may be true, the early course of a neurodegenerative
illness provides important phenotype information as well.
Furthermore, evidence is accumulating that many cases of dementia
are multi-factorial in origin and a single diagnosis may not capture this
complexity. For example, AD frequently overlaps with dementia with
Lewy bodies5 and vascular disease.6 Up to 30% of non-demented
elderly people have significant amyloid pathology.7 Some researchers
have even advocated the idea that, rather than being considered
definitive diagnoses, some diagnoses should be considered additive
‘‘risk factors’’ for dementia, an idea that has received some support in
large pathology series.8
Finally, all medical fields have their own values and culture that can
influence our assessment of illness. Many patients with dementia,
especially non-Alzheimer’s dementia, are treated and studied by non-
behavioral neurologists who, I would argue, often place more
diagnostic importance on some classes of symptoms, such as motor
symptoms, and less on others, such as psychiatric and behavioral
changes. While there are significant barriers to the assessment of
psychiatric and behavioral symptoms in neurodegenerative disorders,
including greater pre-morbid variability in behavior than in motor
function and that psychiatric illness is common in patients without
neurodegenerative disease, this bias can impede our understanding of
the underlying biology of these illnesses. For several dementing
illnesses, including Huntington’s Disease and FTD, psychiatric and
behavioral changes appear to be the most common early symptoms of
the illness.9 And some motor disorders that were thought for many
years to spare behavior, cognition, and emotion, such as ALS, are now
recognized to often be associated with symptoms in these domains.
Clinical–pathological disagreement in dementia has practical
ramifications. It can lead to incorrect prognosis and exposure to
unnecessary medications. It can greatly diminish the power of clinical
trials of medications that are targeted toward a particular pathology.
For example, if a response rate to a medication is 50%, a 20%
misdiagnosis rate would lower the actual response rate to 40%,
necessitating a doubling of sample size to maintain statistical power.10
What are ways this situation could be improved? Biomarkers of
specific neuropathologies have already improved our ability to
determine the neuropathology underlying some causes of dementia
and will continue to do so. In addition, to more accurately assess the
probability of clinical–pathological agreement in a given patient, I
suggest that we reframe the job of the clinician diagnosing dementia.
Rather than a one-step process of determining the underlying
neuropathology of a patient, the role of the diagnostician could be seen
as a two-step process: To first define the clinical syndrome, then
determine the probabilities of different neuropathological correlates of the
clinical syndrome. The patient and family should be educated on the
difference between clinical and pathological diagnoses, and that the
clinical diagnosis may change over time. In my experience, this can help
prepare the family for later changes in clinical diagnosis or clinical–
pathological disagreement. Cases of clinical–pathological disagreement
should not necessarily be considered an incorrect clinical diagnosis, but
may instead reflect true and important heterogeneity of the illness. That is,
both the clinical and pathological diagnoses were correct, but for reasons
not yet fully understood, the clinical phenotype differed from the most
common phenotype associated with that neuropathology. Research to
define clinical syndromes of dementing disorders should carefully assess
the entire range of potential symptoms from motor to emotional. Finally,
Bayesian probabilities, currently used implicitly by clinicians diagnosing
patients with dementia, could be integrated more explicitly into the
diagnostic process to improve diagnostic accuracy and the evaluation of
new biomarkers (e.g., as a field we may accept lower sensitivities and
specificities for diagnostic tests used to detect rare causes of dementia).
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